KRAS G12D突变晚期非小细胞肺癌用药治疗研究进展
Research Progress of Drug Therapy for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer
DOI: 10.12677/acm.2026.1641330, PDF,   
作者: 吴志轩, 肖梓婷, 梁家梓, 杨兆收*：广东药科大学第一临床医学院，广东 广州
关键词: 非小细胞肺癌；KRAS G12D；靶向治疗；Non-Small Cell Lung Cancer； KRAS G12D； Targeted Therapy
摘要: 本文旨在阐述KRAS G12D突变晚期非小细胞肺癌的用药治疗进展，目前治疗方案的效果以及国内外治疗研究进展，重点阐述靶向治疗的最新临床数据及其作用机制，分析其在临床应用中面临的挑战，并对未来可能出现的新的治疗手段进行展望，以期为KRAS G12D突变晚期NSCLC的临床治疗决策提供思路。
Abstract: The purpose of this paper is to describe the progress of drug therapy for advanced non-small cell lung cancer with KRAS G12D mutation, focusing on the effect of current treatment regimens and the research progress of treatment at home and abroad, expounding the latest clinical data of targeted therapy and its mechanism of action, analyzing the challenges it faces in clinical application, and looking forward to new treatment methods that may appear in the future, in order to provide ideas for clinical treatment decisions of advanced NSCLC with KRAS G12D mutation.
文章引用：吴志轩, 肖梓婷, 梁家梓, 杨兆收. KRAS G12D突变晚期非小细胞肺癌用药治疗研究进展[J]. 临床医学进展, 2026, 16(4): 976-985. https://doi.org/10.12677/acm.2026.1641330

参考文献

[1] Skoulidis, F., Byers, L.A., Diao, L., Papadimitrakopoulou, V.A., Tong, P., Izzo, J., et al. (2015) Co-Occurring Genomic Alterations Define Major Subsets of kras-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. Cancer Discovery, 5, 860-877. [Google Scholar] [CrossRef] [PubMed]
[2] Shahnam, A., Davis, A., Brown, L.J., Sullivan, I., Lin, K., Ng, C., et al. (2025) Real-World Outcomes of Non-Small Cell Lung Cancer Patients Harbouring KRAS G12C and KRAS G12D Mutations. Lung Cancer, 201, Article 108421. [Google Scholar] [CrossRef] [PubMed]
[3] 张波, 钟润波, 钟华. 《中华医学会肺癌临床诊疗指南(2025版)》更新要点解读[J]. 中华肿瘤杂志, 2025, 47(10): 981-986.
[4] Pinto, L.M., Rocha, P., Clave, S., Gorro, N.N., Sanchez, I., Giner, M., et al. (2023) 193P Differences in Response to Immunotherapy between KRAS G12C and KRAS Non-G12C Mutated NSCLC. Journal of Thoracic Oncology, 18, S145-S146. [Google Scholar] [CrossRef] 
[5] Pinto, L.M., Parreira, A.S.D.F.M., Unanua, N.C., et al. (2023) 1408P Differences on Immune Biomarkers between KRAS G12C and KRAS Non-G12c Mutated Non-Small Cell Lung Cancer. Annals of Oncology, 34, S805-S806. [Google Scholar] [CrossRef] 
[6] Jin, H., Huang, H., Wu, Y., Zhang, Y., Xu, J., Liu, T., et al. (2026) Efficacy of First-Line Immunochemotherapy across KRAS Mutation Subtypes in Advanced Lung Adenocarcinoma. International Journal of Cancer. [Google Scholar] [CrossRef] 
[7] 朱琳, 穆传勇. KRAS(G12D+),STK11共突变伴PD-L1高表达的晚期肺腺癌患者1例[J]. 当代医药论丛, 2025(5): 149-152.
[8] Pinto, L.M., Clave, S., Sánchez, I., Perera-Bel, J., Berenguer-Molins, P., Bódalo-Torruella, M., et al. (2025) 383P: KRAS G12C vs. Non-G12C Non-Small Cell Lung Cancer (NSCLC): Insights from Gene Expression Analysis. Journal of Thoracic Oncology, 20, S224-S225. [Google Scholar] [CrossRef] 
[9] Lu, J., Hu, M., Zhao, Y., Chu, T., Zhang, W., Zhou, Y., et al. (2025) Co-Inhibition of the MEK/RTK Pathway Has High Therapeutic Efficacy in KRAS-Mutant Non-Small Cell Lung Cancer. Signal Transduction and Targeted Therapy, 10, Article No. 299. [Google Scholar] [CrossRef] 
[10] Han, B., Lu, J., Zhong, H., Chu, T., Zhang, W., Hu, M., et al. (2024) 1306P Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant Non-Small Cell Lung Cancer: A Single-Center, Open-Label, Single-Cohort Study. Annals of Oncology, 35, S831. [Google Scholar] [CrossRef] 
[11] Han, B., Lu, J., Zhong, H., Chu, T., Zhang, W., Hu, M., et al. (2024) P3.12E.02 MEK Inhibitor Combined with RTK Inhibitor (Trametinib Plus Anlotinib) in Non-G12C KRAS-Mutant Non-Small Cell Lung Cancer: A New Strategy. Journal of Thoracic Oncology, 19, S351. [Google Scholar] [CrossRef] 
[12] Arbour, K.C., Tawee, T., Yaeger, R., Parikh, A.R., Oberstein, P., Papadopoulos, K.P., et al. (2025) Abstract CT019: Preliminary Safety and Antitumor Activity of Zoldonrasib (RMC-9805), an Oral, RAS(ON) G12D-Selective, Tri-Complex Inhibitor in Patients with KRAS G12D Non-Small Cell Lung Cancer (NSCLC) from a Phase 1 Study in Advanced Solid Tumors. Cancer Research, 85, CT019. [Google Scholar] [CrossRef] 
[13] Lu, S., Li, Z., Ai, X., Wu, L., Chen, P., Niu, Z., et al. (2025) MA02.07 Efficacy and Safety of GFH375 in Advanced Non-Small Cell Lung Cancer Patients with KRAS G12D Mutation. Journal of Thoracic Oncology, 20, S59-S60. [Google Scholar] [CrossRef] 
[14] Xie, L., Xu, C., Si, H., Fu, X., Yang, X., Jin, J., et al. (2026) Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRAS G12D Inhibitor. Cancer Discovery, 2026, 1-29. [Google Scholar] [CrossRef] 
[15] Desai, J., Markman, B., Millward, M., Garralda, E., Wainberg, Z.A.A., Gutierrez, M., et al. (2025) 916O Preliminary Phase I Results of INCB161734, a Novel Oral KRAS G12D Inhibitor, in Patients with Advanced or Metastatic Solid Tumors. Annals of Oncology, 36, S559-S560. [Google Scholar] [CrossRef] 
[16] Yoshinari, T., Nagashima, T., Ishioka, H., Inamura, K., Nishizono, Y., Tasaki, M., et al. (2025) Discovery of KRAS(G12D) Selective Degrader ASP3082. Communications Chemistry, 8, Article No. 254. [Google Scholar] [CrossRef] [PubMed]
[17] Nagashima, T., Yoshinari, T., Nishizono, Y., Tasaki, M., Inamura, K., Ishioka, H., et al. (2023) Abstract 5735: Novel KRAS G12D Degrader ASP3082 Demonstrates in Vivo, Dose-Dependent KRAS Degradation, KRAS Pathway Inhibition, and Antitumor Efficacy in Multiple KRAS G12D-Mutated Cancer Models. Cancer Research, 83, Article 5735. [Google Scholar] [CrossRef] 
[18] Park, W., Kasi, A., Spira, A.I., Berlin, J.D., Wang, J.S., Herzberg, B., et al. (2024) 608O Preliminary Safety and Clinical Activity of ASP3082, a First-in-Class, KRAS G12D Selective Protein Degrader in Adults with Advanced Pancreatic (PC), Colorectal (CRC), and Non-Small Cell Lung Cancer (NSCLC). Annals of Oncology, 35, S486-S487. [Google Scholar] [CrossRef] 
[19] Yan, S., Ye, Z., Chen, H., Ding, C., Xu, J. and Feng, Y. (2025) Abstract 1648: LT-010366, a First-in-Class Orally Bioavailable KRAS G12D Degrader in the Treatment of Multiple KRAS G12D-Mutated Cancer Models in Vitro and in Vivo. Cancer Research, 85, 1648-1648. [Google Scholar] [CrossRef] 
[20] Ji, X., Li, H., Wu, G., et al. (2025) Discovery and Characterization of RP03707: A Highly Potent and Selective KRASG12D PROTAC. Journal of Medicinal Chemistry, 68, 10238-10254.
[21] Yang, Y.N., Yen, S.C., Liao, C.N., Lee, Y.S. and Tsai, K.C. (2024) 153 (PB141): DCBCI2203, a Novel Protein Degrader Targeting KRAS G12D/V. European Journal of Cancer, 211, Article 114675. [Google Scholar] [CrossRef] 
[22] Weller, C., Burnett, G.L., Jiang, L., Chakraborty, S., Zhang, D., Vita, N.A., et al. (2025) A Neomorphic Protein Interface Catalyzes Covalent Inhibition of RAS G12D Aspartic Acid in Tumors. Science, 389, eads0239. [Google Scholar] [CrossRef] [PubMed]
[23] Kale, R., Samant, C., Nandakumar, K., Ranganath Pai, K.S. and Bhonde, M. (2025) Drugging the Undruggable and Beyond: Emerging Precision Oncology Approaches to Target Acquired Resistance to KRAS G12C and KRAS G12D Inhibitors. Biochemical and Biophysical Research Communications, 760, Article 151688. [Google Scholar] [CrossRef] [PubMed]
[24] Endrino, I.P., Gunder, L., Massad, M., Carretero, J. and Shimamura, T. (2025) Abstract 5521: Integrative Analysis of Acquired Drug Resistance to KRAS(G12D) Inhibitors. Cancer Research, 85, 5521-5521. [Google Scholar] [CrossRef] 
[25] Li, Y., Zhao, J. and Li, Y. (2025) New Exploration of KRASG12D Inhibitors and the Mechanisms of Resistance. Experimental Hematology & Oncology, 14, Article No. 39. [Google Scholar] [CrossRef] [PubMed]
[26] Dilly, J., Hoffman, T.M., Abbassi, L., et al. (2024) Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Cancer Discovery, 14, 2135-2161.
[27] Wang, X., Ding, L., Sun, S., et al. (2025) CASTOR1: A Novel Tumor Suppressor Linking mTORC1 and KRAS Pathways in Tumorigenesis and Resistance to KRAS-Targeted Therapies in Non-Small Cell Lung Cancer. bioRxiv.
[28] 王高明, 崔然, 黎彦璟, 等. KRAS R68G继发突变引发KRAS(G12D)靶向抑制剂MRTX1133耐药的机制研究[J]. 上海交通大学学报(医学版), 2025, 45(6): 705-716.
[29] Marinelli, D., Pisegna, S., Giammaruco, M., Chesi, P., Mammone, G., Ceddia, S., et al. (2021) 3MO Oncogenic Non-G12C KRAS Mutations in KRAS G12C Mutated Lung Adenocarcinomas in TRACERx and GENIE: A Reservoir for Intrinsic Resistance to KRAS G12C Inhibitors. Annals of Oncology, 32, S1345-S1346. [Google Scholar] [CrossRef] 
[30] Jiang, X., Wang, T., Zhao, B., Sun, H., Dong, Y., Ma, Y., et al. (2025) KRASG12D-Driven Pentose Phosphate Pathway Remodeling Imparts a Targetable Vulnerability Synergizing with MRTX1133 for Durable Remissions in PDAC. Cell Reports Medicine, 6, Article 101966. [Google Scholar] [CrossRef] [PubMed]
[31] 胡龙淼. 新型泛KRAS抑制剂的抗肿瘤活性研究[D]: [博士学位论文]. 上海: 华东师范大学, 2024.
[32] Wang, T., Ibanez, M., Yu, K., Fan, K., Juan, J., Perez, M., et al. (2024) 8 Oral: ALTA3263: An Oral, KRAS Isoform-Selective, Dual on/off State, Noncovalent Inhibitor Induces Regressions across KRAS G12V, G12D, and G12C Cancer Models. European Journal of Cancer, 211, Article 114537. [Google Scholar] [CrossRef] 
[33] Lee, N., Li, Y., Liu, G., Li, J., Yang, M. and Song, Z. (2025) Abstract 4380: HBW-016-K, a Novel Orally Available Pan-KRAS Inhibitor Targeting Both “on” and “off” States, Is Potent, Selective, Efficacious, Safe, and High Tissue-Penetrant. Cancer Research, 85, 4380-4380. [Google Scholar] [CrossRef] 
[34] Zeng, M.S., Yang, J., Wang, Q.L.W., et al. (2025) Abstract 6896: A Pan-KRAS Degrader for the Treatment of KRAS-Mutant Cancers. Cancer Research, 85, 6896-6896. [Google Scholar] [CrossRef] 
[35] Chikkanna, D., Aeluri, M., Khare, L., MV, R., Basak, D., Bhat, U., et al. (2025) Abstract 7017: Discovery and Development of a Highly Co-Operative and Potent Pan-KRAS Degrader. Cancer Research, 85, 7017-7017. [Google Scholar] [CrossRef] 
[36] Poss, M., Zhou, C., Lu, C., Zhang, R., Wang, Y., Xiong, Y., et al. (2025) Abstract 4384: SYNB021225: A Potent Oral Pan-KRAS Peptide Inhibitor That Can Address Unmet Needs of Small Molecule Inhibitors. Cancer Research, 85, 4384-4384. [Google Scholar] [CrossRef] 
[37] Tanaka, Y., Tsukuda, M., Yamamoto, G., Sugiyama, E., Izumi, H., Sakai, T., et al. (2025) Abstract 7198: Preclinical Efficacy of the Combination of MEK Inhibitor Plus KRAS G12D Inhibitor for Non-Small Cell Lung Cancer with KRAS G12D. Cancer Research, 85, 7198-7198. [Google Scholar] [CrossRef] 
[38] Jiang, L., Menard, M., Weller, C., Burnett, G.L., Maldonato, B., Wang, Z., et al. (2024) 300 (PB288): Combination of RAS(ON) Multi-Selective and G12D-Selective Inhibitors Improves Antitumor Activity and Enhances Antitumor Immunity in Preclinical Models of KRASG12D-Driven Cancers. European Journal of Cancer, 211, Article 114814. [Google Scholar] [CrossRef] 
[39] Wainberg, Z.A., Chung, V., Devoe, C.E., George, T.J., Welkowsky, E., Kheoh, T., et al. (2024) AMPLIFY-7P: Phase 1 and Randomized Phase 2 Study of Amphiphile Immunotherapy ELI-002 7P as Adjuvant Treatment for Subjects with G12D, G12R, G12V, G12C, G12A, G12S and G13D Kirsten Rat Sarcoma (KRAS)-Mutated Pancreatic Ductal Adenocarcinoma. Journal of Clinical Oncology, 42, TPS720. [Google Scholar] [CrossRef] 
[40] Ng, M., Hoffmann, M., Zygiel, E., McQuown, A., Brate, A., Naheed, S., et al. (2024) 1066 T Cell Engagers Targeting HLA-A11:01 KRAS-G12D and KRAS-G12V Mutations for Cancer Immunotherapy. Immuno-Conjugates and Chimeric Molecules, 12, A1186. [Google Scholar] [CrossRef] 
[41] Shirvan, M., Racheli, M., Yaron, M., et al. (2025) SIL-204 siRNA Encapsulated in Extended Release Microparticles for the Treatment of Localized Cancer That Harbors a KRAS G12x or G13D Mutation. Journal of Clinical Oncology, 43, 745-745. [Google Scholar] [CrossRef] 
[42] Aredo, J.V., Padda, S.K., Kunder, C.A., Han, S.S., Neal, J.W., Shrager, J.B., et al. (2019) Impact of KRAS Mutation Subtype and Concurrent Pathogenic Mutations on Non-Small Cell Lung Cancer Outcomes. Lung Cancer, 133, 144-150. [Google Scholar] [CrossRef] [PubMed]
[43] Sun, L., Handorf, E.A., Zhou, Y., Borghaei, H., Aggarwal, C. and Bauman, J. (2024) Outcomes in Patients Treated with Frontline Immune Checkpoint Inhibition (ICI) for Advanced NSCLC with KRAS Mutations and STK11/KEAP1 Comutations across PD-L1 Levels. Lung Cancer, 190, Article 107510. [Google Scholar] [CrossRef] [PubMed]
[44] Arbour, K.C., Jordan, E., Kim, H.R., Dienstag, J., Yu, H.A., Sanchez-Vega, F., et al. (2018) Effects of Co-Occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. Clinical Cancer Research, 24, 334-340. [Google Scholar] [CrossRef] [PubMed]
[45] Cooper, A.J., Muzikansky, A., Lennerz, J., Narinesingh, F., Mino-Kenudson, M., Hung, Y.P., et al. (2022) Clinicopathologic Characteristics and Outcomes for Patients with KRAS G12D-Mutant NSCLC. JTO Clinical and Research Reports, 3, Article 100390. [Google Scholar] [CrossRef] [PubMed]
[46] McDaid, W.J., Wilson, L., Adderley, H., Martinez-Lopez, A., Baker, M.J., Searle, J., et al. (2024) The PI3K-AKT-mTOR Axis Persists as a Therapeutic Dependency in KRASG12D-Driven Non-Small Cell Lung Cancer. Molecular Cancer, 23, Article No. 253. [Google Scholar] [CrossRef] [PubMed]
[47] Ernst, S.M., Aldea, M., von der Thüsen, J.H., de Langen, A.J., Smit, E.F., Paats, M.S., et al. (2025) Utilizing ctDNA to Discover Mechanisms of Resistance to Targeted Therapies in Patients with Metastatic NSCLC: Towards More Informative Trials. Nature Reviews Clinical Oncology, 22, 371-378. [Google Scholar] [CrossRef] [PubMed]

为你推荐